The FDA has dropped its complaint against fitness tracker company Whoop over its blood pressure monitoring feature, reversing its earlier demand that the tool be disabled.
The reversal marks a significant shift in the agency's regulatory stance toward Whoop's wearable device. The FDA initially took issue with the blood pressure tracking capability, viewing it as a medical device requiring regulatory clearance.
Whoop's blood pressure tool allows users to monitor cardiovascular health through its wrist-worn tracker. The feature had drawn FDA scrutiny over classification and approval pathways, leading to the agency's initial complaint.
The withdrawal suggests either a resolution between Whoop and the FDA regarding the tool's claims and functionality, or a reassessment by the agency of how consumer health tracking features should be regulated.
This outcome could have implications for other wearable manufacturers offering similar health monitoring capabilities. The fitness tracker market continues to expand its health-focused features, creating ongoing questions about where regulators draw lines between consumer wellness tools and medical devices.
Whoop has not yet publicly commented on the FDA's decision.
Japanese flash memory maker Kioxia Holdings saw executive compensation jump sharply, driven by soaring global demand for AI-related semiconductors and rising stock valuations.
Memory and semiconductor stocks tumbled Tuesday, with Micron and SanDisk leading losses at over 13% as a broader tech correction took hold across the sector.
Chinese battery maker CATL is accelerating sodium-ion battery deployment this year to support energy storage needs driven by AI infrastructure expansion. The company is also exploring computing power from idle electric vehicles.
Semiconductor stocks suffered one of their worst trading days this year, raising questions about the sustainability of equity market gains that have been heavily concentrated in a narrow group of high-performing tech names.